Keros Therapeutics, 6 Eyl\u00fcl 2025 Cumartesi g\u00fcn\u00fc Amerikan Kemik ve Mineral Ara\u015ft\u0131rmalar\u0131 Derne\u011fi'nin 2025 Y\u0131ll\u0131k Toplant\u0131s\u0131'nda sa\u011fl\u0131kl\u0131 erkek g\u00f6n\u00fcll\u00fcler \u00fczerinde ger\u00e7ekle\u015ftirdi\u011fi KER-065 Faz 1 klinik denemesinden elde edilen ek klinik verileri sundu\u011funu duyurdu.<\/p>\n\n\n\n
Ba\u015fkan ve \u0130cra Kurulu Ba\u015fkan\u0131 Jasbir S. Seehra, "KER-065'nin g\u00fc\u00e7l\u00fc kemik anabolik aktivitesi de dahil olmak \u00fczere geni\u015f terap\u00f6tik potansiyelini vurgulayan ek veriler sunmaktan mutluluk duyuyoruz," dedi. "Bu veriler, ilerleyen kas g\u00fc\u00e7s\u00fczl\u00fc\u011f\u00fc ve kronik kortikosteroid kullan\u0131m\u0131 sonucu kemik kayb\u0131n\u0131n meydana geldi\u011fi Duchenne kas distrofisinde KER-065'nin potansiyelini g\u00f6stermeye devam ediyor."<\/p>\n\n\n\n
Bu Faz 1 klinik \u00e7al\u0131\u015fma, sa\u011fl\u0131kl\u0131 erkek g\u00f6n\u00fcll\u00fcler \u00fczerinde y\u00fcr\u00fct\u00fclen randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc, iki a\u015famal\u0131 doz art\u0131r\u0131m\u0131 (tek doz ve \u00e7oklu artan doz) \u00e7al\u0131\u015fmas\u0131d\u0131r. Bu \u00e7al\u0131\u015fman\u0131n temel ama\u00e7lar\u0131, KER-065'nin g\u00fcvenli\u011fini, tolere edilebilirli\u011fini ve farmakokineti\u011fini de\u011ferlendirmekti. Ke\u015fifsel sonlan\u0131m noktalar\u0131 aras\u0131nda kemik, ya\u011f dokusu, kas, kalp dokusu ve fibrozis \u00fczerindeki farmakodinamik etkinin de\u011ferlendirilmesi yer almaktad\u0131r. Bu \u00e7al\u0131\u015fmadan elde edilen ilk veriler Mart 2025'te raporlanm\u0131\u015ft\u0131r. Devam\u0131n\u0131 oku<\/a> \u2013<\/p>\n\n\n\n 29 Nisan 2025 tarihli son veri kesme tarihi itibar\u0131yla, KER-065 tedavisi test edilen t\u00fcm doz seviyelerinde genel olarak iyi tolere edilmi\u015ftir. Doz s\u0131n\u0131rlay\u0131c\u0131 toksisite veya ciddi advers olay bildirilmemi\u015ftir. Tedaviyle ili\u015fkili 4. derece bir advers olay (kreatin kinaz seviyelerinde y\u00fckselme) g\u00f6zlenmi\u015f, ancak bu olay\u0131n tedaviyle ili\u015fkili olmad\u0131\u011f\u0131 de\u011ferlendirilmi\u015ftir. G\u00f6zlemlenen advers olaylar\u0131n \u00e7o\u011fu hafif ila orta \u015fiddette olup, iyile\u015fmi\u015ftir.<\/p>\n\n\n\n Bu denemeden elde edilen ek sonu\u00e7lar, veri kesme tarihi itibar\u0131yla KER-065 ile tedavinin \u015fu sonu\u00e7lar\u0131 verdi\u011fini g\u00f6stermi\u015ftir:<\/p>\n\n\n\n KER-065, aktivin resept\u00f6r\u00fc tip IIA ve aktivin resept\u00f6r\u00fc tip IIB'den t\u00fcretilen ve Fc alan\u0131 olarak bilinen insan antikorunun bir k\u0131sm\u0131na kayna\u015ft\u0131r\u0131lm\u0131\u015f modifiye edilmi\u015f bir ligand ba\u011flanma alan\u0131ndan olu\u015fan yeni bir ligand tuza\u011f\u0131d\u0131r. KER-065, bir ligand tuza\u011f\u0131 g\u00f6revi g\u00f6recek ve aktivin resept\u00f6rleri arac\u0131l\u0131\u011f\u0131yla sinyal g\u00f6nderen iki ligand olan miyostatin ve aktivin A'n\u0131n biyolojik etkilerini inhibe edecek \u015fekilde tasarlanm\u0131\u015ft\u0131r. Bu ligandlar, iskelet kas\u0131 rejenerasyonunu, kas boyutunu ve g\u00fcc\u00fcn\u00fc art\u0131r\u0131r, v\u00fccut ya\u011f\u0131n\u0131 azalt\u0131r, iskelet kas\u0131 fibrozunu azalt\u0131r ve kemik g\u00fcc\u00fcn\u00fc art\u0131r\u0131r.<\/p>","protected":false},"excerpt":{"rendered":" Keros Therapeutics announced that it presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the American Society of Bone and Mineral Research 2025 Annual Meeting on Saturday, September 6, 2025. \u201cWe are pleased to present additional data that highlights the broad therapeutic potential of KER-065, including its […]<\/p>\n","protected":false},"author":1,"featured_media":4439,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[337,336],"class_list":["post-4416","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-ker-065","tag-keros-therapeutics"],"subtitle":"Modifiye Aktivin Resept\u00f6r Ligand Tuza\u011f\u0131 KER-065'nin Sa\u011fl\u0131kl\u0131 Kat\u0131l\u0131mc\u0131larda Ger\u00e7ekle\u015ftirilen 1. Faz Denemesi, Duchenne Kas Distrofisi ve Kemik Bozukluklar\u0131nda Geli\u015fimi Destekliyor.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=4416"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4416\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/4439"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=4416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=4416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=4416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
KER-065 nedir?<\/h2>\n\n\n\n